Brilliant Futures™ Myopia Management Program with MiSight® 1 day Contact Lenses Now Available at Hōkūʻula Eyecare
Kamuela, Hawai’i – Hōkūʻula Eyecare announced that it is offering the Brilliant Futures™ Myopia Management Program with MiSight® 1 day contact lenses. These are first and only soft contact lenses designed for myopia control and FDA-approved* to slow myopia progression in children, aged 8-12 at initiation of treatment.†¹
“When we learned about the Brilliant Futures™ Myopia Management Program, we immediately wanted to offer it in our practice,” stated Lori Kim, O.D.. “Myopia, also known as nearsightedness, is increasing at an alarming rate, especially among school-aged children.² We believe that this program, which utilizes the MiSight® 1 day contact lenses, is going to have a large impact on our age-appropriate patients.”
CooperVision’s research into the effectiveness of the MiSight® 1 day contact lenses included a multi-year study that enrolled 144 children with myopia, aged 8-12, from Singapore, Canada, the United Kingdom and Portugal.³ After 3 years, the data showed that the contact lenses were proven to slow myopia progression by 59% on average.³ After 6 years, nearly one in four eyes originally fit with MiSight® 1 day had no progression of myopia.**4
“We are proud to be one of the first in the area offering this revolutionary approach to myopia management,” commented Dr. Kim.
To determine if the Brilliant Futures™ Myopia Management Program with MiSight® 1 day is right for your 8 to 12 year old child, or to make an appointment, please visit www.hokuulaeyecare.com.
Indications and Important Safety Information
- Rx only
- Results may vary.
ATTENTION: Reference the Patient Information Booklet for a complete listing of Indications and Important Safety Information. *Indication: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters(spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. Warnings: Problems with contact lenses could result in serious injury to the eye. Do not expose contact lenses to water while wearing them. Under certain circumstances MiSight® lenses optical design can cause reduced image contrast/ghosting/halo/glare in some patients that may cause diffculties with certain visually-demanding tasks.
Precautions: Daily wear single use only. Patient should always dispose when lenses are removed. No overnight wear. Patients should exercise extra care if performing potentially hazardous activities. Adverse events: Including but not limited to infection/inflammation/ulceration/abrasion of the cornea, other parts of the eye or eyelids. Some of these adverse reactions can cause permanent or temporary loss of vision. If you notice any of the stated in your child, immediately have your child remove the lenses and contact your eye care professional.
†Compared to a single vision 1 day lens over a 3 year period.
** -0.25D or less of change. Lenses fitted between the ages of 8-12 at initiation of treatment.
References:
¹Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8): 556-567.
² Cooper Y. (2019, May 1). With Childhood Myopia Rates on the Rise, the American Optometric Association Highlights the Importance of Early Intervention through Annual Eye Exams. Retrieved from https://www.aoa.org/newsroom/myopia-rates-on-the-rise-syvm.
³CooperVision data on file 2019. Chamberlain P, Logan N, Jones D, Gonzalez-Meijome J, Saw S-M, Young G. Clinical evaluation of a dual-focus myopia control 1 day so contact lens: 3-year results (2016 American Academy of Optometry Annual Meeting) and 5-year results (2019 BCLA Clinical Conference & Exhibition).
4 Chamberlain P, et al. Myopia Progression in Children wearing Dual-Focus Contact Lenses: 6-year findings. Optom Vis Sci 2020;97(E-abstract):200038.